Quetiapine
DrugDosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
NCT Number: NCT00237393
The purpose of the study is to determine if quetiapine is effective in the treatment of PTSD.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
NM VA Healthcare System, Albuquerque, New Mexico, United States
Objective: To assess the impact of quetiapine on core PTSD symptoms and associated psychiatric comorbidity including depressive and positive and negative psychotic symptoms.
Research Design: 12-week, double-blind, placebo-controlled, randomized, fixed-flexible dose trial of quetiapine monotherapy.
Intervention: Eligible patients will be randomized to receive quetiapine starting at 25 mg daily or matching placebo. Dose adjustments (to a minimum of 50 mg or a maximum of 800 mg), will be made at the investigator's discretion and according to patient's clinical response.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
Ralph H. Johnson VA Medical Center
Fed
A Randomized, Placebo-Controlled Trial of Quetiapine (Seroquel) Monotherapy in the Treatment of PTSD
Acronym: PTSD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06403449
Mental Disorders, PTSD
Linxia, Gansu, China
View Trial DetailsNCT04523922
Alcohol Use Disorder, Alcohol-Related Disorders
Charleston, South Carolina, United States
View Trial DetailsNCT06868446
Mental Disorders, PTSD
Tallahassee, Florida, United States
View Trial DetailsNCT03778307
Endothelial Dysfunction, Mental Disorders
Los Angeles, California, United States
View Trial Details